Sonora Investment Management LLC lifted its position in Pfizer Inc. (NYSE:PFE) by 3.6% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 276,622 shares of the biopharmaceutical company’s stock after purchasing an additional 9,698 shares during the period. Pfizer comprises approximately 0.8% of Sonora Investment Management LLC’s portfolio, making the stock its 22nd biggest holding. Sonora Investment Management LLC’s holdings in Pfizer were worth $10,022,000 at the end of the most recent reporting period.
Other institutional investors have also recently modified their holdings of the company. Kinloch Capital LLC bought a new position in shares of Pfizer in the fourth quarter worth approximately $25,000. Alpha DNA Investment Management LLC bought a new position in shares of Pfizer in the fourth quarter worth approximately $26,000. Penbrook Management LLC bought a new position in shares of Pfizer in the fourth quarter worth approximately $27,000. Orion Capital Management LLC bought a new stake in Pfizer in the fourth quarter valued at $29,000. Finally, Merrion Investment Management Co LLC bought a new stake in Pfizer in the fourth quarter valued at $30,000. Hedge funds and other institutional investors own 67.36% of the company’s stock.
Shares of NYSE:PFE traded down $0.15 during mid-day trading on Tuesday, reaching $39.68. 416,853 shares of the company traded hands, compared to its average volume of 31,749,029. The company’s 50 day moving average price is $37.02 and its 200-day moving average price is $36.78. The firm has a market cap of $221.32 billion, a PE ratio of 25.70, a PEG ratio of 2.79 and a beta of 0.70. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.40 and a quick ratio of 1.13. Pfizer Inc. has a 52 week low of $31.61 and a 52 week high of $43.08.
The firm also recently declared a quarterly dividend, which will be paid on Friday, June 4th. Investors of record on Friday, May 7th will be issued a $0.39 dividend. The ex-dividend date of this dividend is Thursday, May 6th. This represents a $1.56 dividend on an annualized basis and a yield of 3.93%. Pfizer’s dividend payout ratio is presently 52.88%.
PFE has been the topic of several recent analyst reports. Berenberg Bank reiterated a “neutral” rating and issued a $38.00 price target on shares of Pfizer in a report on Tuesday, March 23rd. TheStreet cut shares of Pfizer from a “b” rating to a “c+” rating in a report on Friday, March 5th. Mizuho lowered their price objective on Pfizer from $44.00 to $42.00 and set a “buy” rating for the company in a research report on Wednesday, February 3rd. DZ Bank reissued a “buy” rating and set a $41.00 price objective on shares of Pfizer in a research report on Wednesday, February 3rd. Finally, Royal Bank of Canada assumed coverage on Pfizer in a research report on Wednesday, April 7th. They set a “sector perform” rating and a $42.00 price objective for the company. Eleven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $38.47.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.
See Also: What Is an EV Stock
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.